← All trials
NCT05288023
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2022
- Primary completion
- Mar 31, 2026
- Completion date
- Mar 31, 2026
- First posted
- Mar 18, 2022
- Last posted
- Sep 7, 2022
- Enrollment
- 250000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- University of California, San FranciscoOverall official - principal investigator
- Bill and Melinda Gates FoundationCollaborator
- Government of NigerCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.